Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Lucid Diagnostics ( (LUCD) ).
On April 23, 2026, Lucid Diagnostics Inc. priced an underwritten public offering of 18,000,000 shares of common stock at $1.00 per share, under an agreement with Canaccord Genuity and BTIG as joint bookrunners. The underwriters agreed to purchase the shares at $0.94 each, implying an underwriting discount, with the deal anchored by a $15 million investment from a fundamental institutional investor supported by a large existing shareholder.
The gross proceeds of the offering are expected to be about $18 million before fees and expenses, and the transaction is scheduled to close on or about April 24, 2026, subject to customary conditions. Lucid plans to use the net proceeds for working capital and general corporate purposes, bolstering its liquidity as it advances commercialization of its esophageal cancer prevention diagnostics and reinforcing institutional investor support for its long-term growth strategy.
The most recent analyst rating on (LUCD) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Lucid Diagnostics stock, see the LUCD Stock Forecast page.
Spark’s Take on LUCD Stock
According to Spark, TipRanks’ AI Analyst, LUCD is a Neutral.
Overall score is weighed down primarily by weak financial performance (structurally negative margins, widening losses, rising leverage, and accelerating cash burn) and bearish technicals (below major moving averages with negative MACD). The earnings call provides a partial offset via stronger test volumes and payer/VA progress, but reimbursement/collection uncertainty and burn rate remain key constraints; valuation offers limited support given negative earnings and no dividend.
To see Spark’s full report on LUCD stock, click here.
More about Lucid Diagnostics
Lucid Diagnostics Inc., a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc., focuses on patients with gastroesophageal reflux disease who are at risk of esophageal precancer and cancer. Its primary products are the EsoGuard Esophageal DNA Test and the EsoCheck Esophageal Cell Collection Device, which aim to enable early, noninvasive detection of esophageal precancer in at-risk patients.
Average Trading Volume: 782,157
Technical Sentiment Signal: Buy
Current Market Cap: $226.5M
See more data about LUCD stock on TipRanks’ Stock Analysis page.